John Parkinson

The latest data highlight ibezapolstat’s effects on gut microbiome health and systemic exposure, crucial for CDI treatment, while also indicating its potential against Bacillus anthracis, prompting plans for a bioterrorism development initiative.

An English modeling study suggests level of protection decreases only very slightly over time and reminds parents to have their children up to date on all vaccinations.

The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.

Maryann Webb’s harrowing, personal experience with C diff, along with her professional work with federal agencies has prepared her for a life in advocacy with the Peggy Lillis Foundation. She wants to see the fecal microbiota transplant become more accessible and is working with Congress to make the infection a notifiable infectious disease.

The federal agency offers guidance for US clinicians and travelers to understand the disease better and employ preventative measures to reduce incidence rates.

Ammara Mushtaq, MD, discusses the underrepresentation of different races during the pandemic, but also the newer efforts to include and represent these communities in smaller, local studies.

A new survey reveals that infectious disease virologists, epidemiologists and clinicians see the need to address gaps in surveillance programs to identify emerging pathogens, public health funding and testing infrastructure capabilities.

Jeanine Thomas, president and founder of MRSA Survivors Network, talks about her personal battle with osteomyelitis, her work as an advocate, and the need for data and awareness to bring it to the forefront again.

Katrine Wallace, PhD, and Eric John Burnett, MD, discuss the distinctions between them and strategies to understand better the information people are consuming.

A large study shows a moderate benefit to taking the antimalarial therapy.

New predictive statistical modeling shows that antimicrobial resistance (AMR) deaths will rise steadily in the coming decades.

The CSL and Arcturus Therapeutics’ vaccine, ARCT-154 (Kostaive), is designed to offer protection against the JN1 strain.

The International Society for Infectious Diseases (ISID) ProMED surveillance system is a way for clinicians and interested ID stakeholders to be aware of local outbreaks and follow-up in response to get more information on them.

The organization's designation for the Bavarian Nordic’s MVA-BN (Jynneos) mpox vaccine is aimed at helping with the public health response, especially in Africa, where incidences rates continue to increase.

Ami Patel, PhD, provides insights on both technologies and how her research center, the Wistar Institute, is involved in DNA vaccine and monoclonal antibody research.

Gilead’s HIV-1 capsid inhibitor, which is a twice-yearly injection, was more effective than a daily Truvada pill in a phase 3 trial.

Crestone’s novel therapy, CRS3123, demonstrated 97% clinical cure rate in small phase 2 study.

Kevin Nguyen, PharmD, offers some insights on some of the challenges in the outpatient setting with regards to stewardship, and novel strategies being utilized.

Our panel discusses this patient group and the challenges associated with their care.

Debra Goff, PharmD, discusses her advocacy around this topic and bringing the stewardship message to dentists about how antibiotic prescribing practices have changed and getting them to recalibrate their thinking and actions in their field.

Benjamin Park, MD, offers insights on the federal agency’s role in AMR.

Jennifer Ronholm, PhD, discusses the novel concept of microbiome protection to create healthier animals and reduce antimicrobial usage.

Amanda Jezek, of the Infectious Diseases Society of America (IDSA), offers some insight on the prospective bill in Congress, as well as other AMR initiatives the organization is involved in.

After Diane Shader Smith lost her daughter, Mallory, to a multidrug resistant infection, she turned her personal tragedy into a mission designed to inform people about antimicrobial resistance (AMR), and have the public coalesce around this expanding medical issue.

In this episode, clinicians discuss challenges associated with these topics and offer management insights on them.

Invivyd’s investigational pemivibart (Pemgarda), which received an FDA emergency use authorization earlier this year, continued to show efficacy in preventing disease onset over a 6-month exploratory period in this patient population.

The town of Plymouth decided to prohibit people from using the parks from dusk to dawn due to concerns over eastern equine encephalitis after a man contracted the rare disease in the state.

In the second part of our interview with Christian Lillis, cofounder and CEO of the Peggy Lillis Foundation, he discusses what the passage of the Peggy Lillis Clostridioides difficile Inclusion Act would do for reporting of the infection as well as the potential ancillary effects around antibiotic development and antimicrobial resistance.

In our latest roundtable series, we cover different aspects of HIV care. In this series, clinicians discuss diagnosis, therapies such as long-acting injectables, treating patients with multidrug resistance and more.

Bavarian Nordic is working to get their MVA-BN (Jynneos) mpox vaccine to those affected in African countries, as well as working towards a clinical trial for the younger pediatric population, and potential regulatory approval in Europe for adolescents.